NCT06438913View on ClinicalTrials.gov

Tezepelumab Treatment in Korean Severe Asthma Patients

Not yet recruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

May 12, 2025

Study Completion Date

December 31, 2026

Conditions

Asthma

Interventions

DRUG

Tezepelumab

Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine suggested to be important in the initiation and continuation of airway inflammation.